Conditional marketing authorisation granted to Enhertu (trastuzumab deruxtecan) in the UK

This antibody drug conjugate is approved for monotherapy treatment of adults with unresectable or metastatic HER2-positive breast cancer, who received 2 or more prior anti-HER2 based regimens. Phase II trial results showed a 61.4% confirmed objective response rate (CORR).

Source:

PharmaTimes